MS-209 Schering

Curr Opin Investig Drugs. 2004 Dec;5(12):1340-7.

Abstract

MS-209, a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated protein-1, is under development by Schering for the potential treatment of multidrug resistant tumors. By March 2003, phase II trials in breast cancer and non-small-cell lung cancer had been initiated.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase II as Topic
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Quinolines / chemistry
  • Quinolines / pharmacology
  • Quinolines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • Quinolines
  • dofequidar